ClinicalTrials.gg
CompletedNCT05506969Updated Jul 29, 2025Results posted

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

A Phase 2 interventional study of rF1V-1018 and rF1V vaccine in Plague, Pneumonic, Plague and Vaccine-Preventable Diseases, sponsored by Dynavax Technologies Corporation. Completed at 6 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Vaccine-Preventable Diseases with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Vaccine-Preventable Diseases · United States.

Enrollment
6th of 15
200 · median 133
Started
2022
the only one that year
Phase 2
Only one
of the 16
Registered
7th of 16
by date
Lead sponsor
1 of 16
Dynavax Technologies Corporation

Among the 16 studies in Vaccine-Preventable Diseases with a site in United States, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 2, and was the 7th registered.

Vaccine-Preventable Diseases

53 studies on the registry are indexed under Vaccine-Preventable Diseases; 12 are open to participants now.

Browse Vaccine-Preventable Diseases studies →

Open to participants now

1 of the 16 studies in Vaccine-Preventable Diseases with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Vaccine-Preventable Diseases studies recruiting now, 2 set no upper age limit and 6 stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Vaccine-Preventable Diseases with a site in United States, or all of them as a file.
02

Study summary

Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age

Read the detailed description

Phase 2, randomized, active-controlled, observer-blind, multicenter trial of the immunogenicity, safety, and tolerability of rF1V vaccine with CpG 1018® adjuvant (rF1V-1018) compared with rF1V vaccine alone in adults. Approximately two hundred healthy adults 18 to 55 years of age will be enrolled to compare a two-dose regimen of rF1V-1018 with a three-dose regimen of rF1V vaccine alone. The study will be conducted in 2 parts (Part 1 and Part 2).

03

Conditions studied

  • Plague, Pneumonic
  • Plague
  • Vaccine-Preventable Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 55 years
  • Healthy participants or participants with pre-existing medical conditions who are in a stable medical condition.

Pre-existing stable medical condition means a subject who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.

  • Able to comply with the protocol schedule and procedures.
  • Able and willing to provide written
  • If female of and heterosexually active, has practiced adequate for 28 days prior to vaccination and has negative pregnancy tests just prior to vaccination and has agreed to continue adequate contraception until 28 days after last study injection. Adequate contraception is defined as a contraceptive method with a failure rate of \< 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. Examples include the following:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
    • Progestin-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable
    • Intrauterine device (IUD) with or without hormonal release
    • Vasectomized partner, provided he is the subject's sole partner and that he has received a medical assessment of the surgical success
    • Credible self-reported history of heterosexual abstinence for at least 28 days prior to vaccine administration
    • Female partner

Exclusion criteria

Exclusion Criteria:

  • A history of plague disease or have previously received any plague vaccine.
  • Active tuberculosis or other systemic infectious process.
  • History of (HIV), (HBV) or (HCV) infection, or positive test for antibody to HIV, HBV, or HCV
  • History of disorder
  • History of sensitivity to any component of study vaccines
  • ≥ 30 kg/m2
  • Has received the following prior to the injection:
  • 14 days:
  • COVID-19 vaccine
  • Any inactivated vaccine
  • 28 days:
  • Any
  • Systemic (more than 3 consecutive days) or other immunomodulators or immunomodulators immune suppressive medication, with the exception of inhaled steroids
  • Any other medicinal agent
  • 90 days:
  • Immunoglobulins or any blood products
  • Granulocyte or granulocyte-macrophage colony-stimulating factor
  • Antisense oligonucleotides
  • Drugs/investigational agents with very long half-lives (defined as ≥ 60 days)
  • At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells
  • If female is pregnant (known before or established at the time of screening), breastfeeding, or planning a pregnancy
  • Is undergoing chemotherapy or expected to receive chemotherapy during the study period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
  • Oral temperature >100.0°F at the time of vaccine administration.
  • History of acute myocardial infarction (AMI) or documented coronary artery disease (CAD)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    rF1V-1018 co-administered (rF1V vaccine and CpG 1018® adjuvant co-administered)

    Co-administration of rF1V vaccine and CpG 1018® adjuvant administered as 2 injections

    Biological: rF1V-1018

  • Experimental
    rF1V-bedside mix (rF1V vaccine and CpG 1018® adjuvant bedside mix)

    Bedside mix of rF1V vaccine and CpG 1018® adjuvant administered administered as 2 injections

    Biological: rF1V-1018

  • Experimental
    rF1V vaccine only

    rF1V vaccine administered as 3 injections

    Biological: rF1V vaccine

Interventions

  • BiologicalrF1V-1018

    rF1V vaccine and CpG 1018® adjuvant

  • BiologicalrF1V vaccine

    rF1V vaccine

06

What researchers measure

Primary outcomes

  1. Rates of Reactogenicity and Safety

    Rates of solicited local and systemic post-injection reactions, and AEs, severe AEs, SAEs, AESIs, and deaths

    Time frame: Day 1 to Week 56

07

Results

Posted Jul 29, 2025

Participant flow

Participant flow — Overall Study
MilestonerF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine Only
Started219089
Completed188177
Not completed3912

Outcome measures

PrimaryRates of Reactogenicity and Safety

Rates of solicited local and systemic post-injection reactions, and AEs, severe AEs, SAEs, AESIs, and deaths

Time frame:
Day 1 to Week 56
Reported as:
Count of participants · Participants
Rates of Reactogenicity and Safety
ParticipantsrF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine Only
Local Reactions166757
Severe Local Reactions002
Systemic Reactions136042
Severe Systemic Reactions020
At least 1 Unsolicited AE72728
Severe (Grade 3 or 4) AEs215
SAEs103
AESIs101
Deaths001

Adverse events

Collected over Participants were followed for post-injection local and systemic reaction for 7 days post each injection and for AEs, SAEs, and imAESIs through Day 393 (Week 56).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rF1V-1018 Co-Administered0/21 (0%)1/21 (4.8%)18/21 (85.7%)
rF1V-1018 Bedside Mix0/90 (0%)0/90 (0%)77/90 (85.6%)
rF1V Vaccine Only1/89 (1.1%)3/89 (3.4%)69/89 (77.5%)
Most frequent serious events
Most frequent serious events
EventrF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine Only
Cor Pulmonale AcuteCardiac disorders1/210/900/89
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/210/900/89
Deep Vein ThrombosisVascular disorders1/210/900/89
Complicated AppendicitisInfections and infestations0/210/901/89
AppendicitisInfections and infestations0/210/901/89
Toxicity to Various AgentsInjury, poisoning and procedural complications0/210/901/89
Most frequent other events
Showing 10 of 11
Most frequent other events
EventrF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine Only
Injection Site PainGeneral disorders16/2166/9056/89
FatigueGeneral disorders10/2143/9030/89
MyalgiaMusculoskeletal and connective tissue disorders9/2123/9022/89
HeadacheNervous system disorders8/2134/9025/89
DiarrhoeaGastrointestinal disorders7/2115/9012/89
MalaiseGeneral disorders6/2125/9021/89
NauseaGastrointestinal disorders4/2113/9012/89
Injection Site PruritusGeneral disorders2/2117/9013/89
ChillsGeneral disorders3/2113/9014/89
UrticariaSkin and subcutaneous tissue disorders2/210/900/89

Baseline characteristics

Safety analysis population: All participants who received at least 1 study injection and had any post-baseline safety data

Age, Customized
Age, Customized(Years)rF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine OnlyTotal
Mean (SD)39.1 ± 8.1740.0 ± 9.237.9 ± 9.9139.0 ± 9.76
Age, Customized
Age, Customized(Participants)rF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine OnlyTotal
18-39124246100
40+94843100
Sex: Female, Male
Sex: Female, Male(Participants)rF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine OnlyTotal
Female9343679
Male125653121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)rF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine OnlyTotal
Hispanic or Latino081018
Not Hispanic or Latino217777175
Unknown or Not Reported0527
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)rF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine OnlyTotal
White146262138
Black or African American4192043
American Indian or Alaska Native1102
Asian1225
Native Hawaiian or Other Pacific Islander0123
Other1539
Body mass index
Body mass index((kg/m^2))rF1V-1018 Co-AdministeredrF1V-1018 Bedside MixrF1V Vaccine OnlyTotal
Mean26.5 ± 2.4625.9 ± 3.0425.5 ± 3.1625.8 ± 3.04
08

Study locations

6 sites
  • Optimal Research Alabama
    Huntsville, Alabama 35802-2569, United States
  • Optimal Research California
    San Diego, California 92108, United States
  • Optimal Research Florida
    Melbourne, Florida 32934-8172, United States
  • Optimal Research Illinois
    Peoria, Illinois 61614-4885, United States
  • Optimal Research Maryland
    Rockville, Maryland 20850, United States
  • Optimal Research Texas
    Austin, Texas 78705-2655, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Oct 2023, 13 months.

Results were first posted in Jul 2025, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 18, 2022
StartActual
Aug 9, 2022
Primary completionActual
Oct 3, 2023
CompletionActual
Apr 26, 2024
Results first posted
Jul 29, 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05506969
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Aug 18, 2022
Start date
Aug 9, 2022
Primary completion
Oct 3, 2023
Completion
Apr 26, 2024
Results posted
Jul 29, 2025
Last update
Jul 29, 2025

Study contacts

Robert Janssen, MD
study chair · Dynavax Technologies Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion